Li, H.; Si, T.; Li, R.; Xie, X.; Liu, Y.; Fu, L.; Bai, Y.; Yao, J.; Zhang, X.; Yang, M.;
et al. Hepatic Arterial Infusion Chemotherapy with Serplulimab and the Bevacizumab Biosimilar HLX04 for Advanced Hepatocellular Carcinoma: A Prospective, Observational Phase II Clinical Trial. Cancers 2025, 17, 3235.
https://doi.org/10.3390/cancers17193235
AMA Style
Li H, Si T, Li R, Xie X, Liu Y, Fu L, Bai Y, Yao J, Zhang X, Yang M,
et al. Hepatic Arterial Infusion Chemotherapy with Serplulimab and the Bevacizumab Biosimilar HLX04 for Advanced Hepatocellular Carcinoma: A Prospective, Observational Phase II Clinical Trial. Cancers. 2025; 17(19):3235.
https://doi.org/10.3390/cancers17193235
Chicago/Turabian Style
Li, Huikai, Tongguo Si, Rentao Li, Xiaojing Xie, Yang Liu, Linlin Fu, Yu Bai, Junchao Yao, Xihao Zhang, Mao Yang,
and et al. 2025. "Hepatic Arterial Infusion Chemotherapy with Serplulimab and the Bevacizumab Biosimilar HLX04 for Advanced Hepatocellular Carcinoma: A Prospective, Observational Phase II Clinical Trial" Cancers 17, no. 19: 3235.
https://doi.org/10.3390/cancers17193235
APA Style
Li, H., Si, T., Li, R., Xie, X., Liu, Y., Fu, L., Bai, Y., Yao, J., Zhang, X., Yang, M., & Mu, X.
(2025). Hepatic Arterial Infusion Chemotherapy with Serplulimab and the Bevacizumab Biosimilar HLX04 for Advanced Hepatocellular Carcinoma: A Prospective, Observational Phase II Clinical Trial. Cancers, 17(19), 3235.
https://doi.org/10.3390/cancers17193235
